ELACESTRANT

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C30H38N2O2
Molecular Weight	458.6349
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of ELACESTRANT

Structure Search

SMILES

[H][C@]1(CCC2=CC(O)=CC=C2C1)C3=C(C=C(OC)C=C3)N(CC)CC4=CC=C(CCNCC)C=C4

InChI

InChIKey=SIFNOOUKXBRGGB-AREMUKBSSA-N

InChI=1S/C30H38N2O2/c1-4-31-17-16-22-6-8-23(9-7-22)21-32(5-2)30-20-28(34-3)14-15-29(30)26-11-10-25-19-27(33)13-12-24(25)18-26/h6-9,12-15,19-20,26,31,33H,4-5,10-11,16-18,21H2,1-3H3/t26-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C30H38N2O2
Molecular Weight	458.6349
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 09:42:51 UTC 2023` Edited by `admin` on `Sat Dec 16 09:42:51 UTC 2023`
Record UNII	FM6A2627A8
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ELACESTRANT

Official Name

English

RAD1901

Code

English

ER-306323

Code

English

RAD-1901

Code

English

(2R)-2-(2-(ETHYL-((4-(2-(ETHYLAMINO)ETHYL)PHENYL)METHYL)AMINO)-4-METHOXY-PHENYL)TETRALIN-6-OL

Systematic Name

English

elacestrant [INN]

Common Name

English

2-NAPHTHALENOL, 6-(2-(ETHYL((4-(2-(ETHYLAMINO)ETHYL)PHENYL)METHYL)AMINO)-4-METHOXYPHENYL)-5,6,7,8-TETRAHYDRO-, (6R)-

Systematic Name

English

ELACESTRANT [USAN]

Common Name

English

Elacestrant [WHO-DD]

Common Name

English

(6R)-6-(2-(ETHYL((4-(2- (ETHYLAMINO)ETHYL)PHENYL)METHYL)AMINO)-4-METHOXYPHENYL)- 5,6,7,8-TETRAHYDRONAPHTHALEN-2-OL

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1821

Created by admin on Sat Dec 16 09:42:51 UTC 2023 , Edited by admin on Sat Dec 16 09:42:51 UTC 2023

Code System Code Type Description

USAN

GH-120

Created by admin on Sat Dec 16 09:42:51 UTC 2023 , Edited by admin on Sat Dec 16 09:42:51 UTC 2023

PRIMARY

CLINICAL_TRIALS.GOV

RAD-1901

Created by admin on Sat Dec 16 09:42:51 UTC 2023 , Edited by admin on Sat Dec 16 09:42:51 UTC 2023

PRIMARY

Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms

NCI_THESAURUS

C120211

Created by admin on Sat Dec 16 09:42:51 UTC 2023 , Edited by admin on Sat Dec 16 09:42:51 UTC 2023

PRIMARY

MANUFACTURER PRODUCT INFORMATION

RAD-1901

Created by admin on Sat Dec 16 09:42:51 UTC 2023 , Edited by admin on Sat Dec 16 09:42:51 UTC 2023

PRIMARY

Description: RAD1901 is an orally available, selective estrogen receptor degrader (SERD) and selective estrogen receptor modulator (SERM), with potential antineoplastic and estrogen-like activities. Upon oral administration of higher doses of RAD1901, this agent acts as a SERD, which binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This may inhibit the growth and survival of ER-expressing cancer cells. At lower doses of this agent, RAD1901 acts as a SERM and has estrogen-like effects in certain tissues, which can both reduce hot flashes and protect against bone loss. In addition, RAD1901 is able to cross the blood-brain barrier (BBB). (last updated: 5/19/2016).Synonym: RAD1901, RAD-1901, RAD 1901, RAD1901 HCl salt.

ChEMBL

CHEMBL3545015

Created by admin on Sat Dec 16 09:42:51 UTC 2023 , Edited by admin on Sat Dec 16 09:42:51 UTC 2023

PRIMARY

SMS_ID

100000170507

Created by admin on Sat Dec 16 09:42:51 UTC 2023 , Edited by admin on Sat Dec 16 09:42:51 UTC 2023

PRIMARY

EVMPD

SUB184531

Created by admin on Sat Dec 16 09:42:51 UTC 2023 , Edited by admin on Sat Dec 16 09:42:51 UTC 2023

PRIMARY

CAS

722533-56-4

Created by admin on Sat Dec 16 09:42:51 UTC 2023 , Edited by admin on Sat Dec 16 09:42:51 UTC 2023

PRIMARY

EPA CompTox

DTXSID901045846

Created by admin on Sat Dec 16 09:42:51 UTC 2023 , Edited by admin on Sat Dec 16 09:42:51 UTC 2023

PRIMARY

DAILYMED

FM6A2627A8

Created by admin on Sat Dec 16 09:42:51 UTC 2023 , Edited by admin on Sat Dec 16 09:42:51 UTC 2023

PRIMARY

DRUG BANK

DB06374

Created by admin on Sat Dec 16 09:42:51 UTC 2023 , Edited by admin on Sat Dec 16 09:42:51 UTC 2023

PRIMARY

FDA UNII

FM6A2627A8

Created by admin on Sat Dec 16 09:42:51 UTC 2023 , Edited by admin on Sat Dec 16 09:42:51 UTC 2023

PRIMARY

PUBCHEM

23642301

Created by admin on Sat Dec 16 09:42:51 UTC 2023 , Edited by admin on Sat Dec 16 09:42:51 UTC 2023

PRIMARY

WIKIPEDIA

Elacestrant

Created by admin on Sat Dec 16 09:42:51 UTC 2023 , Edited by admin on Sat Dec 16 09:42:51 UTC 2023

PRIMARY

INN

10247

Created by admin on Sat Dec 16 09:42:51 UTC 2023 , Edited by admin on Sat Dec 16 09:42:51 UTC 2023

PRIMARY

Related Record Type Details


					SIDP85PFD6

ESTROGEN RECEPTOR

TARGET->INHIBITOR, RECEPTOR DEGRADER

Amount:


					8NZT0PR8AL

ELACESTRANT HYDROCHLORIDE

SALT/SOLVATE -> PARENT

Amount:

Related Record Type Details


					FM6A2627A8

ACTIVE MOIETY

Comments:

Class: Osteoporosis therapy, Small molecule, Tetra-hydro-naphthalene; Mechanism of Action: Selective estrogen receptor degraders, Selective estrogen receptor modulator; Highest Development Phases: Phase II for Vasomotor symptoms, Phase I for Breast cancer; Most Recent Events: 08 Feb 2016 Radius, in collaboration with Novartis, plan a clinical trial for RAD 1901 in combination with LEE 011 in the treatment of Breast cancer, 27 Jan 2016 Radius Health and Novartis enter into a clinical collaboration to evaluate combination regimens, RAD 1901 and ricociclib, for the treatment of Breast cancer, 01 Dec 2015 Phase-II clinical trials in Vasomotor symptoms in USA (PO) (NCT02653417)

Amount: